21 results about "HUVEC Cells" patented technology

The invention relates to the field of natural medicinal chemistry, and discloses an efficient separation and preparation method of a compound theanine diglucoside TFG. Although TFG structures are reported, separation from tea leaves is not disclosed. According to the invention, an efficient separation and purification method is established for the first time, and TFG is accurately extracted and identified from tea leaves by combining an HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector) guided multi-stage column chromatography technology with nuclear magnetic resonance and mass spectrometry. Experiments prove that the TFG activates an antioxidant pathway, improves H2O2-induced HUVEC cell and HT22 cell damage, protects the vascular endothelial barrier function and neuronal activity, and is suitable for developing antioxidant drugs for treating Alzheimer's disease. Compared with the prior art, the invention fills the blank of separation of the tea-derived TFG, explores the new application of the tea-derived TFG in the field of cell protection, and provides a new thought for natural product development and functional food research.

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.

The application belongs to the technical field of cell culture, and particularly relates to umbilical cord blood-derived endothelial cell culture additives, an endothelial cell culture method and application. The umbilical cord blood-derived endothelial cell culture additives comprise activated platelet-rich plasma and at least one of miR-132 and miR-193b-3p high expression and miR-155 low expression exosomes. The application further provides an endothelial cell culture medium comprising the umbilical cord blood-derived endothelial cell culture additives, and the culture medium can significantly improve the growth state of HUVEC cells and effectively reduce or even avoid the vacuolization phenomenon in the culture process.

The invention belongs to the field of medicines, and particularly relates to an in-vitro evaluation model for promoting skin wound healing based on a VPA-Exo drug-loaded exosome as well as a construction method and application of the in-vitro evaluation model. The construction method of the in-vitro evaluation model for promoting skin wound healing comprises the following steps: S1, after passage of resuscitated HSF cells and HUVEC cells, taking HSF cells or HUVEC cell suspension in a logarithmic phase, inoculating the HSF cells or HUVEC cell suspension on a culture plate, and culturing on a real-time label-free cell analyzer for 20-28 hours; and S2, then adding VPA-EXO with the concentration of 12.5 mu g / mL-400 mu g / mL to act on the HSF cells or the HUVEC cells.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

This application belongs to the field of biomaterials, specifically relating to an antibacterial polymeric derivative of F127 with terminal modification of acetyl bromide, its preparation method, and its application. This application obtains F127AcBr by terminal modification of polymeric F127 with acetyl bromide via an acylation reaction. Its good antibacterial effect and biocompatibility were verified in vitro using plate antibacterial assays against Staphylococcus aureus and Escherichia coli, as well as live / dead staining assays of L929 cells and HUVEC cells. This application optimized the concentration of F127AcBr and loaded it into an MS hydrogel system. Excellent biocompatibility was confirmed in a diabetic mouse wound model using HE staining of mouse organs. Immunofluorescence staining against Staphylococcus aureus further confirmed the good antibacterial activity of F127AcBr.

The application is suitable for the technical field of nanocluster preparation, and provides reversible control fluorescent gold nanoclusters and a preparation method thereof, which comprises the following steps: adding 4mM chloroauric acid solution 221µL into a CK solution with a concentration of 2mM 443µL after being fully dissolved, then adding 2M NaOH 14.7µL, adjusting the pH value of the solution to 13, immediately mixing, wrapping with tin paper, transferring to a shaking incubator for reaction for 10h, and obtaining H-AuNCs with bright red fluorescence. 60µM H-AuNCs are co-granted with HUVEC cells for 2h, and bright red fluorescence is formed in the cells, so that biological imaging can be realized. The powder obtained by drying the H-AuNCs is transferred into a dimethyl sulfoxide solution to obtain organic phase D-AuNCs with bright blue fluorescence. The application prepares CK-AuNCs with high fluorescence intensity, and can realize reversible adjustment of the fluorescence color.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.

The invention discloses a 2 '-alpha-ethynyl-beta-fluoronucleoside compound which has a structure as shown in a formula I, and pharmaceutically acceptable salts or various optical isomers, solvates or prodrugs thereof, and is a compound targeting a new structure of RNA (Ribonucleic Acid) virus polymerase. The invention also discloses a preparation method of the compound, a composition containing the compound and application of the compound in preparation of drugs for treating virus infection diseases. The 2 '-alpha-ethynyl-beta-fluoronucleoside compound obtained by the invention shows a remarkable chain termination intervention effect in a CCHFV polymerase system, an SARS-CoV-2 polymerase system and an EV71 polymerase system. The result of a cellular level inhibition experiment shows that the 2 '-alpha-ethynyl-beta-fluoronucleoside compound has an obvious inhibition effect on CCHFV on an HUVEC cell.

The invention relates to controllably degradable silicified DNA hydrogel and a preparation method and application thereof, the hydrogel is assembled into a three-dimensional network through a DNA structure with a single-chain region in the center and a linear DNA structure, and the mechanical property and thermal stability of the hydrogel are improved through in-situ silicification. The precisely designed single-chain region can still be recognized and degraded by specific nuclease after silicification, so that precisely controlled selective degradation is realized. The material takes human umbilical vein endothelial cells as an example, good biocompatibility of the material is verified, and the material can be used for cell embedding and releasing and is suitable for research and application fields of advanced biological materials, medicine, pharmacy and the like, such as organoid culture, tissue engineering, controllable drug release and the like.

The present application belongs to the technical field of bioengineering, and particularly relates to a tuna fish bone antioxidant oligopeptide and a preparation method thereof.The tuna fish bone antioxidant oligopeptide has good scavenging activity, and has good thermal stability and digestion resistance; the mechanism of action is to promote the release of nitric oxide (NO), improve the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), catalase (CAT) and total antioxidant capacity (T-AOC), and reduce the levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH); JQYG-1 can protect HUVEC cells from oxidative damage induced by hydrogen peroxide; JQYG-1 can exert an antioxidant effect and protect vascular endothelial cells, and can provide a candidate drug for the prevention and treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, cerebral thrombosis, myocardial infarction, atherosclerosis and heart failure.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of H2AC19 in the detection and treatment of lung adenocarcinoma. Specifically, this invention demonstrates that H2AC19 is abnormally highly expressed in lung adenocarcinoma patients, and this high expression is significantly associated with poor prognosis. Knockout of H2AC19 inhibits angiogenesis and tumor growth in vitro and in vivo, and reduces the proliferation, migration, and tube formation capabilities of lung adenocarcinoma cells in a co-culture model with human umbilical vein endothelial cells. Furthermore, this invention reveals a novel mechanism by which H2AC19 regulates angiogenesis through the p300 / EGR1 / MMP-1 pathway. This invention not only provides a superior method for the diagnosis and prognostic assessment of lung adenocarcinoma, but also lays an experimental foundation and expands new perspectives for the development of highly effective drugs for treating lung adenocarcinoma, thus possessing significant practical application value.

The application provides a nucleic acid molecule, a pro-angiogenic mesenchymal stromal cell and application thereof, relates to the biomedical technical field, and the nucleic acid molecule encodes HGF protein, or encodes VEGF165 protein and HGF protein; a first signal peptide is used as the signal peptide of the VEGF165 protein, and a second signal peptide is used as the signal peptide of the HGF protein. Through a gene modification strategy, MSC cells containing the nucleic acid molecule can stably and efficiently express VEGF165 and / or HGF, and the expression amount is significantly higher than that of MSC without the nucleic acid molecule. The cells have the ability to promote the migration of endothelial cells; meanwhile, the cells can also significantly promote the proliferation and tube formation of HUVEC cells, and further confirm the strong pro-angiogenic effect. The technical problem that nucleic acid molecules expressing VEGF165 or / HGF cannot be stably and efficiently expressed in the prior art is solved.

The invention provides a polypeptide-modified bacterial outer membrane vesicle and application thereof in preparation of a drug for promoting cell growth, and relates to the technical field of biological medicines. According to the invention, a growth promoting polypeptide VTPYGGGGVLLY with a brand new structure is designed on the basis of two micromolecular polypeptides VTPY and VLLY from sea cucumbers, and the engineering bacterial outer membrane vesicle W-VTPVLY OMV with a relatively strong growth promoting effect is prepared by combining the growth promoting polypeptide VTPYGGGGVLLY with bacterial outer membrane protein ClyA by utilizing a genetic engineering technology. The W-VTPVLY OMV provided by the invention has a remarkable promoting effect on HUVEC cell proliferation, migration and revascularization, can play a role in promoting cell proliferation within a short time, and can maintain the proliferation promoting effect for a relatively long time. The W-VTPVLY OMV provided by the invention is expected to become a new medicine for promoting wound regeneration and tissue healing, and provides a new thought and application reference for the fields of tissue engineering and medical materials.

The application discloses a preparation method of bone organ-derived extracellular vesicles and application of the bone organ-derived extracellular vesicles in promoting angiogenesis. The application comprises the following steps: culturing bone marrow mesenchymal stem cells after osteogenic induction in a three-dimensional culture to construct bone organs, transfecting Hif-1 alpha plasmid, collecting bone organ culture supernatants of different culture time, separating and extracting extracellular vesicles through ultracentrifugation to obtain bone organ-derived extracellular vesicles (BOEVs) rich in BMP-2, TGF-beta 1, HIF-1 alpha and VEGF. The BOEVs are co-cultured with HUVEC cells, and the results show that the BOEVs can significantly promote the lumen formation and branching of the HUVEC cells by about 5 times, and up-regulate the expression of angiogenesis-related genes VEGF and CCN2, indicating that the BOEVs can promote angiogenesis.

Cryopreservation of endothelial cell monolayers is one of the major challenges in the cryopreservation of complex tissues. Human umbilical vein endothelial cells (HUVECs) in suspension are available commercially and recently their post-thaw cell membrane integrity was significantly improved by cryopreservation in 5% dimethyl sulfoxide (DMSO) and 6% hydroxyethyl starch (HES). However, cryopreservation of cells in monolayers has been elusive. The exact mechanisms of damage during cell monolayer cryopreservation are still under investigation. Here, we show that a combination of different factors contribute to significant progress in cryopreservation of cell monolayers. The addition of 2% chondroitin sulfate to 5% DMSO and 6% HES and cooling at 0.2 or 1° C. / min led to high membrane integrity (97.3±3.2%) immediately after thaw when HUVECs were cultured on a substrate with a coefficient of thermal expansion similar to that of ice. The optimized cryopreservation protocol was applied to monolayers of primary porcine corneal endothelial cells, and resulted in high post-thaw viability (95.9±3.7% membrane integrity) with metabolic activity 12 hours post-thaw comparable to unfrozen control.

The invention discloses application of avenanthramide D in preparation of a medicine for inhibiting angiogenesis, and relates to the technical field of biological medicine. Avenanthramide D is applied to intervene HUVEC cells, cell viability, cell apoptosis rate and angiogenesis ability after intervention are detected, and it is found that avenanthramide D can inhibit HUVEC cell proliferation, promote HUVEC cell apoptosis and inhibit HUVEC cell angiogenesis. A further experiment shows that the avenanthramide D reduces the integrity of an endothelial barrier by reducing the protein expression of a vascular endothelial growth factor A (VEGFA) and a platelet endothelial cell adhesion molecule 1 (CD31) in HUVEC cells, so that angiogenesis is blocked.

The present invention discloses a schizophyllan polysaccharide having two molecular weights of 1.54×10 7 Da and 1.85×10 4 The components of Da are composed of glucose, mannose, galactose, and fucose, with the molar ratio of glucose, mannose, galactose, and fucose being 86:8:5:1. The schizophyllan is a non-homopolymeric polysaccharide with glucose as its main component, which can promote the proliferation of HaCaT cells and HUVEC cells. At the same time, the schizophyllan can significantly accelerate the healing rate of wounds in mice with full-thickness skin wound models, and has excellent effects in epithelial re-formation, granulation tissue formation, and tissue remodeling. When 4 mg / mL of schizophyllan is used to treat mouse wounds, the healing rate reaches 96.65%.

The invention discloses a small molecule polypeptide capable of being used as a type 5 phosphodiesterase inhibitor and application of the small molecule polypeptide. The polypeptide is hexapeptide, and the amino acid sequence is FRPPAL. According to the invention, a molecular docking technology is adopted to screen out PDE5 protein with high affinity (binding energy lt; and 10.0 kcal / mol) of the polypeptide sequence. And carrying out solid-phase synthesis and in-vitro enzyme inhibition activity evaluation on the optimal sequence, and finally identifying the candidate polypeptide with remarkable PDE5 inhibition activity. When the mass concentration of the FRPPAL is 100 [mu] M, the inhibition rate of the FRPPAL on the PDE 5 is 31.81%. A subsequent cell experiment shows that when the concentration of FRPPAL reaches 200 [mu] M, the survival rate of HUVEC cells is 97.16%, and the HUVEC cells have no obvious cytotoxicity, so that the HUVEC cells have excellent medical treatment potential. In addition, the micromolecule polypeptide is easy to absorb, is not easy to degrade by gastrointestinal tract protease, and can be orally taken.

The invention discloses a copper (II) complex with anticancer activity as well as a preparation method and application thereof, and belongs to the technical field of complexes. According to the preparation method, CuCl22H2O, CuBr2 or Cu (NO3) 2.3 H2O is subjected to a reaction with benzoyl hydrazone 3-acetyl-7-N, N-diethylamino coumarin respectively, and the complex is obtained. The obtained complex has certain anti-proliferative activity to four cell lines, namely HeLa, MCF-7, A549 and HepG-2, and the anti-proliferative activity is obviously superior to that of a ligand, particularly, the complex shows relatively excellent anti-proliferative activity to the MCF-7 cell line, and the toxicity to normal HUVEC cells is also obviously lower than that of cis-platinum. The copper (II) complex provided by the invention has good anti-cancer activity, the preparation method is simple, the toxicity is small, and a new thought is provided for the development of anti-cancer drugs.